Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name

- Organization/Lobbying Firm
- Self Employed Individual

AstraZeneca Pharmaceuticals LP

2. Address

- Address1: 1800 CONCORD PIKE, P.O. BOX 15437
- Address2: 

- City: WILMINGTON
- State: DE
- Zip Code: 19850-5437
- Country: USA

3. Principal place of business (if different than line 2)

- City: 
- State: 
- Zip Code: 
- Country: 

4a. Contact Name

Ms. Jamie Bell

b. Telephone Number

2023505550

c. E-mail

jamie.bell@astrazeneca.com

5. Senate ID#

54073-12

6. House ID#

349750000

7. Client Name

- Self

- Check if client is a state or local government or instrumentality

AstraZeneca Pharmaceuticals LP

8. Year

2019

Q1 (1/1 - 3/31)

Q2 (4/1 - 6/30)

Q3 (7/1 - 9/30)

Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report

Termination Date

11. No Lobbying Issue Activity

INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13

12. Lobbying

INCOME relating to lobbying activities for this reporting period was:

- Less than $5,000

- $5,000 or more

$300,000

Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSE relating to lobbying activities for this reporting period were:

- Less than $5,000

- $5,000 or more

$450,000.00

14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.

- Method A. Reporting amounts using LDA definitions only

- Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

- Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature

Digitally Signed By: Jamie Bell

Date

10/20/2019

8:36:09 PM
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

- Value of Prescription Drugs
- Drug Pricing Transparency
- Oncology Care Model
- Personalized Medicine
- Diagnostics
- S. 1895, Lower Health Care Costs Act
- HR 3 drug pricing bill

17. House(s) of Congress and Federal agencies  
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Centers For Disease Control & Prevention (CDC)

18. Name of each individual who acted as a lobbyist in this issue area

<table>
<thead>
<tr>
<th>First Name</th>
<th>Last Name</th>
<th>Suffix</th>
<th>Covered Official Position (if applicable)</th>
<th>New</th>
</tr>
</thead>
<tbody>
<tr>
<td>Natalie</td>
<td>Morris</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Helen</td>
<td>Dwight</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morgan</td>
<td>Bradley-Jones</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Susie</td>
<td>Ahn</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Julie</td>
<td>Garner</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

19. Interest of each foreign entity in the specific issues listed on line 16 above  
Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

- Medicare Part D Coverage and Reimbursement
- Medicare Part D Non-Interference
- Legislative proposals to change Medicare Part D; Rebate Rule
- Medicare Part B coverage and reimbursement
- Changes to the Medicaid Drug Rebate Program (AMP Cap)
- Medicare Part B Intl. Pricing Index ANPRM
- 14 Day Rule
- End State Renal Disease PPS
- Senate Finance drug pricing package
- HR 3 drug pricing bill

17. House(s) of Congress and Federal agencies  

- U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

<table>
<thead>
<tr>
<th>First Name</th>
<th>Last Name</th>
<th>Suffix</th>
<th>Covered Official Position (if applicable)</th>
<th>New</th>
</tr>
</thead>
<tbody>
<tr>
<td>Natalie</td>
<td>Morris</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Helen</td>
<td>Dwight</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morgan</td>
<td>Bradley-Jones</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Susie</td>
<td>Ahn</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Julie</td>
<td>Garner</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

19. Interest of each foreign entity in the specific issues listed on line 16 above  

- Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

- Medicare Part D coverage and reimbursement
- Value of Prescription Drugs
- Prescription Drug Importation
- Innovative Payment Models
- Price Transparency
- Legislative proposals to change Medicare Part D
- Medicaid and 340B issues & drug discount program
- President’s Drug Pricing Blueprint
- H.R. 1499, Protecting Consumer Access to Generic Drugs Act
- S. 1416, Affordable prescriptions for Patients Act
- S. 64, H.R. 2375, Preserve Access to Affordable Generics and Biosimilars Act

17. House(s) of Congress and Federal agencies  

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

<table>
<thead>
<tr>
<th>First Name</th>
<th>Last Name</th>
<th>Suffix</th>
<th>Covered Official Position (if applicable)</th>
<th>New</th>
</tr>
</thead>
<tbody>
<tr>
<td>Natalie</td>
<td>Morris</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Helen</td>
<td>Dwight</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morgan</td>
<td>Bradley-Jones</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Susie</td>
<td>Ahn</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Julie</td>
<td>Garner</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

19. Interest of each foreign entity in the specific issues listed on line 16 above  

Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

- FDA Patent Settlement legislation
- Intellectual property and patent issues
- S. 340, H.R. 965 CREATE Act
- S. 1209, REMEDY Act
- S. 1224, H.R. 2374, Stop STALLING Act

17. House(s) of Congress and Federal agencies ☐ Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

<table>
<thead>
<tr>
<th>First Name</th>
<th>Last Name</th>
<th>Suffix</th>
<th>Covered Official Position (if applicable)</th>
<th>New</th>
</tr>
</thead>
<tbody>
<tr>
<td>Helen</td>
<td>Dwight</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morgan</td>
<td>Bradley-Jones</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Susie</td>
<td>Ahn</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Natalie</td>
<td>Morris</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Julie</td>
<td>Garner</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

19. Interest of each foreign entity in the specific issues listed on line 16 above  ☑ Check if None

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address
City ___________________________ State ________ Zip Code _________ Country ________

21. Client new principal place of business (if different than line 20)

City ___________________________ State ________ Zip Code _________ Country ________

22. New General description of client’s business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

<table>
<thead>
<tr>
<th>First Name</th>
<th>Last Name</th>
<th>Suffix</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ISSUE UPDATE
24. General lobbying issue that no longer pertains

25. Add the following affiliated organization(s)

Internet Address:

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>Principal Place of Business</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1
2
3

27. Add the following foreign entities:

<table>
<thead>
<tr>
<th>Name</th>
<th>Address</th>
<th>Principal place of business</th>
<th>Amount of contribution for lobbying activities</th>
<th>Ownership percentage in client</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1
2
3
4
5
6

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

☐ No ☐ Yes

<table>
<thead>
<tr>
<th>Lobbyist Name</th>
<th>Description of Offense(s)</th>
</tr>
</thead>
</table>